🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

BRIEF-J&J Announces Agreement With U.S. Government For 100 Mln Doses Of Investigational Covid-19 Vaccine

Published 2020-08-05, 08:38 a/m

Aug 5 (Reuters) - Johnson & Johnson JNJ.N :

* JOHNSON & JOHNSON ANNOUNCES AGREEMENT WITH U.S. GOVERNMENT FOR 100 MILLION DOSES OF INVESTIGATIONAL COVID-19 VACCINE

* J&J - BARDA IN COLLABORATION WITH U.S. DEPARTMENT OF DEFENSE, IS COMMITTING OVER $1 BILLION FOR AGREEMENT

* J&J - VACCINE WILL BE PROVIDED AT A GLOBAL NOT-FOR-PROFIT BASIS FOR EMERGENCY PANDEMIC USE

* J&J - EVALUATING ONE- AND TWO-DOSE REGIMENS FOR COVID-19 VACCINE IN ITS CLINICAL PROGRAM

* J&J - U.S. GOVERNMENT MAY ALSO PURCHASE AN ADDITIONAL 200 MILLION DOSES OF AD26.COV2.S UNDER A SUBSEQUENT AGREEMENT

* J&J - AIMS TO MEET ITS GOAL TO SUPPLY MORE THAN ONE BILLION DOSES GLOBALLY THROUGH COURSE OF 2021, PROVIDED VACCINE IS SAFE AND EFFECTIVE

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.